Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: Disclosed herein are novel drug eluting contact lenses configured to release one or more compounds that inhibit phosphodiesterase 1 (PDE1). The PDE1 inhibitors may be administered as monotherapy or in combination with additional pharmaceutical agents in the treatment of an ophthalmic disease, disorder or injury. Related methods of use and treatment are also disclosed.

Abstract: In variants, the method for automatic debris detection includes: determining a region image; optionally determining a parcel representation for the region image; generating a debris representation using the region image; generating a debris score based on the debris representation; and optionally monitoring the debris score over time.

Abstract: A method, system, apparatus, and/or device to determine a condition of a user based on a heartbeat waveform. The method, system, apparatus, and/or device may include: a miniaturized impedance sensor configured to take a measurement from a muscular-walled tube within a body part of a user, where the miniaturized impedance sensor includes a first set of miniaturized electrodes configured to generate a signal within the muscular-walled tube and a second set of miniaturized electrodes configured to measure the signal; and a processing device programmed to interrogate the muscular-walled tube via the miniaturized impedance sensor. The processing device may be configured to generate the signal by the first set of miniaturized electrodes; measure the signal by the second set of miniaturized electrodes; generate a heartbeat waveform; and determine a condition of the user based on the heartbeat waveform.

Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, for use in methods for the treatment or prevention of opiate addiction relapse.

Abstract: An orchestration layer includes one or more processing devices communicatively coupled to a plurality of domains in a multi-domain network, wherein the one or more processing devices are configured to receive a request for a path, wherein the path is requested from a source in a first domain to a destination in a second domain in a multi-domain network including a plurality of domains, relay the request to each domain in the multi-domain network, and wherein each domain in the multi-domain network is configured to compute a matrix fragment and the matrix fragments from a plurality of domains are used to find the path, and provide a response with the path from the source in the first domain to the destination in the second domain.

Abstract: The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of cancers and tumors, including for inhibiting tumor recruitment of macrophages and other cells to the tumor or cancer, for complementing and enhancing checkpoint inhibitor therapies, and for mitigating the side effects (i.e., inflammatory-related adverse events) associated with checkpoint inhibitor therapies.

Abstract: The invention relates to particular prodrugs and analogs of (3?,5?)-3-hydroxy-21-(1H-imidazol-1-yl)-3-methoxymethyl)-pregnan-20-one, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as sedatives, hypnotics, anxiolytics, and/or anesthetics, and methods for treatment of depression, anxiety, insomnia, epilepsy, and other central nervous system disorders, as well as to combinations with other agents.

Abstract: An aircraft hubcap/wheel cover which uses ambient airflow (120 mph-175 mph) to rotate wheels on the landing gear of an aircraft accomplished by using slightly protruding slats, blades, scoops or other air capturing shapes, (once the landing gear has been lowered). These air capturing shapes are integrated as part of the hubcap/wheel cover during manufacture and are directly determined by ground speed applicable to that aircraft with the ultimate purpose being tire longevity. The wheel cover hubcap is a single piece design and has no moving parts.

Abstract: The invention relates to a particular enantiomer of a substituted heterocycle fused gamma-carboline, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, and pathways involving the dopamine D1 and D2 receptor signaling system.

Abstract: The invention relates to a particular substituted heterocycle fused gamma-carboline, in free, or pharmaceutically acceptable salt, and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), and/or pathways involving the dopamine D1 and D2 receptor signaling system.

Abstract: A relatively dry, relatively free flowing cannabinoid concentrate composition having a plant extract and a thickening agent. The cannabinoid concentrate composition may have a variety of cannabinoids, drying agents, flowing agents, and/or stabilization agents. The mixture may be a dry powder formulation similar to the consistency of flour or sand. The mixture may comprise a cannabinoid raffinate, an isolated cannabinoid, maltodextrin, and or silica.

Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.

Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Abstract: A Liquid Crystal Waveguide (LCW) system can provide sub-aperture incoupling or outcoupling of light having an input wavelength and input beamsize defining an aperture characteristic of the system. A Liquid Crystal Waveguide (LCW) can include a generally planar LCW core to receive light via a light input zone for communication toward a light output zone. Sub-aperture interfacial light couplers can be planarly arranged in or parallel to the planar LCW core in the light input zone or the light output zone. Sub-aperture interfacial light couplers can include teeth, prisms, or facets, a photonic crystal metasurface, or a geometric-phased holograph (GPH)). Overall LCW thickness can be reduced, which can be helpful in space-limited applications or for reducing material costs.

Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

Abstract: The disclosure provides new transdermal pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.

Abstract: An optical system for receiving light scanned from different light origination locations in space can include a Liquid Crystal (LC) waveguide (LCW), including first and second LCW light ports. A beamsteering LC electrode can be included in or coupled to the LCW and can be configured to vary a receiving direction of light received at the second LCW light port in response to a varying electrical input signal applied to the LC electrode to scan receiving of light at the second LCW light port from different light origination locations in space. A photodetector can be optically coupled to the first LCW light port, such as to detect waveguided light from different light origination locations in space received in response to the varying electrical input signal applied to the first LC electrode. Ranger, bright-spot locking, laser detection, direct detect and coherent lidar, wavelength detection, and other techniques and use cases are possible.